Clinical Trial

A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
TQB2934 is an anti-Cluster of Differentiation 3 (CD3) (Early T Cell Marker)×B cell maturation antigen (BCMA) double-specific antibody，and the isoform is IgG1(Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells. TQB2934 for injection (subcutaneous injection) is intended for the treatment of patients with multiple myeloma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-16.
Status change: Not Yet Recruiting → Recruiting 2025-12-10
Trial Details
NCT Number NCT07179679
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Multiple Myeloma
Enrollment 42 participants
Start Date 2025-12-09
Primary Completion 2027-10 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-11